Synthetic LXR agonists including TO901317 and GW3965 cross the blood-brain barrier (BBB), induce ABCA1 and apoE expression, improve memory and reduce Aβ levels in AD mice [42]–[44]. The gene discussed is APOE; the disease is Alzheimer disease.